Full Description
This book is a comprehensive and up-to-date compendium on diagnosis, treatment and late effects of Acute Lymphoblastic Leukemia (ALL) in children, adolescents and young adults. After introductory chapters on the epidemiology and biology of ALL, treatment considerations are extensively reviewed, also with emphasis on special patient groups, such as Infants, Adolescents and patients with Down Syndrome. Immunotherapy in Acute Lymphoblastic Leukemia is reviewed as well as strategies for patients with Lymphoblastic Lymphoma and for patients with refractory or relapsed ALL. The authors are internationally recognized experts and offer up-to-date insights on etiology, biology, and treatment. This book will prove indispensable for those treating or researching into this disease.
Contents
Part I: Epidemiology and Predisposition of ALL. Genetic predisposition for leukemia.- Association of leukemia with genetic diseases. Part II: Biology and Diagnostics of ALL. Genetic aberrations and profiles in Bcp ALL.- Genetic aberrations and profiles in T ALL.- Features of ALL in children, adolescents, and young adults.- Immunological Diagnosis.- MRD response: FCM, Ig/Tcr PCR, NGS. Part III: Stratification and treatment considerations in ALL. Stratification and treatment of Bcp ALL and T-ALL.- Stratification and treatment of Adolescents/AYA.- CNS therapy .- Stratification and treatment of Down Syndrome .- Stratification and treatment of Infants.- Stratification and treatment of BCR/ABL and ABL class fusion. Part IV: Immunotherapy in ALL. Immunotherapy with monoclonal antibodies.- Immunotherapy with CAR-T. Part V: Strategies for patients with Lymphoblastic Lymphoma/mature B-ALL. Stratification and treatment of lymphoblastic lymphomas.- Stratification and treatment of mature B ALLs. Part VI: Strategies for patients with refractory or relapsed ALL. Relapses: classification and treatment.- HSCT in 1rst CR and after subsequent CRs: indications, conditioning regimens. Part VII: Toxicity and Late effects following ALL treatment. Genetic disposition for toxicity Late toxicity including SMN.- late effects after HSCT. Part VIII: Perspectives and Future directions.- Global disparities in ALL treatment and outcome.- New agents.
